23 Sep 2015
Rational drug design
C4XD is developing its own pipeline of drug discovery programmes. The addiction programme’s lead candidate, a selective OX1 antagonist, is in formal preclinical studies. Two further programmes are expected to show preclinical proof of concept by the year-end. The proprietary technology platform enables improved and accelerated drug discovery based on conformational design of solution structures. Collaborations with pharma and research companies on novel drug programmes provide both platform validation and steady, albeit modest, revenues (£0.6m in 2014).